Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas
Cubist Pharmaceuticals LLC
This study is designed to investigate the difference in speed and degree of symptom
resolution between daptomycin and vancomycin in subjects treated for cellulitis or
erysipelas by evaluation of the following parameters:
- Time to erythema margin cessation to progress
- Time to defervescence
- Time to hospital discharge following relief of the presenting cellulitis or erysipelas
- Degree of improvement of the following signs and symptom of cellulitis or erysipelas
- Degree of improvement of cellulitis-related pain and swelling as reported by subjects
Additionally, the difference in frequency of Adverse Events between daptomycin and
vancomycin will be described.
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
Cubist Pharmaceuticals LLC
multicenter, randomized, double blind study to describe the safety and efficacy of
daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination
therapy in the treatment of SAIE
China Registration Study in Patients With Skin Infections
The objectives of this study is to evaluate the Safety and Efficacy of Intravenous
Daptomycin (Cubicin®)Compared with that of Comparator (Vancomycin or Vancomycin Followed by
Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects with Complicated
Bacterial Skin and Skin Structure Infection due to Gram-Positive Pathogens.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.